Moderna’s phase-1 trials show experimental coronavirus vaccine can induce immune response

Moderna's COVID-19 vaccine has shown promising results by triggering an immune response in all volunteers during preliminary testing. The mRNA in the vaccine instructs body cells to produce proteins that mimic the coronavirus spike proteins, helping the immune system recognize and combat the virus. The phase 1 trial involved three groups with varying dosages, and those receiving two doses showed higher antibody levels than recovered COVID-19 patients. However, some volunteers experienced severe side effects, including high fever and nausea.

What was the main outcome of the preliminary testing of Moderna's vaccine?

How does the mRNA in the vaccine function in the body?

What dosage regimen was used for the volunteers in the trial?

What was the significance of the antibody levels found in participants who received two doses of the vaccine?

What were the side effects experienced by some volunteers during the trial?